INTRODUCTION {#S1}
============

Since the original description of recurrent gene fusions in prostate cancer involving *TMPRSS2* and *ETV1* or *ERG* ([@R1]), the list of putative recurrent gene fusions continues to grow ([@R2]). As initially observed, these fusions most commonly involve an ETS family member gene fused to a 5 prime (5\') hormonally regulated promoter, most often *TMPRSS2*([@R3]). Few reports have focused on trying to determine how common a particular gene fusion occurs in a population. Over twenty studies from independent research groups (recently reviewed by Tomlins *et al*. ([@R4]) and Clark and Cooper ([@R5])) suggest that *ERG* rearrangement can be observed in 40--60% of prostate cancers identified through prostate-specific antigen (PSA) screening. These studies were predominately based on the evaluation of tumor samples from men who underwent surgery for clinically localized disease. Mosquera *et al*. recently reported a frequency of *ERG* rearrangement in 46% of cases in a prospective PSA-screened prostate cancer biopsy cohort ([@R6]).

There is mounting data suggesting that *ERG* rearranged prostate cancer has several distinct features defining a sub-class of this common epithelial neoplasm. First, mouse model studies over expressing *ERG* alone ([@R7], [@R8]) or in the context of *PTEN* loss ([@R9], [@R10]) demonstrate a neoplastic phenotype. Second, associations between histomorphologic features and *ERG* rearrangement have been observed ([@R6], [@R11]). Third, molecular profiles suggest distinct alterations in pathways, specifically estrogenic signaling, in *ERG* rearranged prostate cancer ([@R12], [@R13]). Forth, distinct somatic copy number alterations are enriched in *ERG* rearranged prostate cancers ([@R14]). Fifth, if left untreated, *ERG* rearranged prostate cancers are associated with an unfavorable clinical course as compared to non-*ERG* rearranged prostate cancer ([@R15], [@R16]). Finally, Attard et al. have demonstrated an *ERG* rearrangement status dependent response to abiraterone acetate, a CYP17 inhibitor ([@R17]). Taken together, *ERG* rearrangement prostate cancer appears to represent a distinct molecular and clinical sub-class of prostate cancer.

Most studies have taken a shorthand to define the *TMPRSS2-ERG* fusion cancers. This is based on the use of a fluorescence *in situ* hybridization (FISH) break apart assay to identify *ERG* rearrangement as indirect evidence for *TMPRSS2-ERG* gene fusion([@R1], [@R18]). *A priori* knowledge of possible 5\' partners involved in ETS rearranged prostate cancers led Han et al. to discover an *ERG* rearranged case to be fused with *SLC45A3* (*Solute carrier family 45, member 3*, also known as Prostein) as the 5\' partner([@R19]). This was the first study to identify an alternate 5\' fusion partner of *ERG*, other than *TMPRSS2*. Up until then, all cases harboring the *ERG* rearrangement were believed to contain the *TMPRSS2-ERG fusion*. To explore for other potential 5\' partners of *ERG*, we recently evaluated all *ERG* rearranged and *ERG* over-expressing cases from a population of 101 samples and confirmed the recurrent nature of *SLC45A3-ERG* fusions. In addition, we discovered *NDRG1* (N-myc Downstream Regulated Gene 1) as a novel 5\' fusion partner by whole transcriptome sequencing *NDRG1* ([@R20]).

In the present study, we analyze a large prostatectomy cohort for the presence of *TMPRSS2-ERG, SLC45A3-ERG, and NDRG1-ERG* fusion events to determine their frequency and potential association with clinical parameters.

MATERIAL AND METHODS {#S2}
====================

Case Selection and Pathologic Analysis {#S3}
--------------------------------------

The cohort consisted of 614 prostate cancer patients who underwent radical prostatectomy between 1999 and 2005 at the Charité Hospital (Berlin, Germany) ([Table 1](#T1){ref-type="table"}). The demographics of this cohort were recently described ([@R21]). In brief, patient age ranged from 43 and 74 years (median 62 years). Preoperative PSA levels ranged from 0.8 to 39 ng/ml (median 7.2 ng/ml). Forty-four patients (7%) had received gonadotropin-releasing hormone analogues at the discretion of the referring urologist, prior to surgery (median 4 weeks, range 2--16 weeks). Clinical follow-up data were reviewed annually. PSA relapse-free survival time was available for 609 patients from this cohort. The median follow-up time of all the cases was 48 months (range 1--108 months) and 89 patients (15%) experienced a PSA relapse after a median time of 13 months (range 1--68). The Gleason scores were distributed as follows: Gleason score 4--6: 217 (35%); Gleason score 7: 291 (48%) Gleason score 8--10: 106 (17%). Organ-confined carcinoma (pT2) was found in 420 patients; 191 showed extraprostatic tumor extension (pT3).

Tissue microarray construction {#S4}
------------------------------

Formalin-fixed paraffin-embedded tissue blocks from radical prostatectomy specimens were used for tissue microarray construction ([@R21]). Two cores (1.0mm) of invasive prostate cancer were chosen, reflecting the primary and secondary Gleason pattern. In addition, normal prostatic tissue was selected for each case.

Assessment of *ERG, TMPRSS2, SLC45A3* and NDRG1 rearrangements using two-color FISH break apart (b/a) assays {#S5}
------------------------------------------------------------------------------------------------------------

Four-micron thick tissue microarray sections were used for interphase FISH analysis. Rearrangement status was determined using a dual-color break-apart interphase FISH assay as described previously ([@R1], [@R18], [@R22]). In brief, two differentially labeled probes were designed to span the telomeric and centromeric neighboring regions of each locus. The following telomeric/centromeric BAC clones were selected to design break-apart assays to assess for rearrangement status (i.e., rearrangement versus no rearrangement): *ERG* (RP11-372O17 and RP11-24A11)*, TMPRSS2* (RP11-120C17 and RP11-35C4)*, SLC45A3* (RP11-131E5 and RP11-249H15), and *NDRG1* (RP11-1145H17 and RP11-185E14). In the case of rearrangement, the assay was also capable of differentiating between two different rearrangement mechanisms (i.e., rearrangement through insertion or rearrangement through deletion) as previously described ([@R18]). A nucleus without a gene rearrangement demonstrates two pairs of juxtaposed red and green signals (mostly forming two yellow signals). A nucleus with a rearrangement through insertion shows the split of one red-green (yellow) signal pair, resulting in a single red and green signal for the rearranged allele, and a still combined (yellow) signal for the non-rearranged allele in each nucleus. Finally, a nucleus with a gene rearrangement through deletion shows one juxtaposed red-green signal pair (yellow) for the non-rearranged allele, and a single red or green signal for the allele involved in the rearrangement. Slides were analyzed under a x60 oil immersion objective using an Olympus (Center Valley, PA) BX-51 fluorescence microscope equipped with appropriate filters and a charge-coupled device camera, and the CytoVision FISH imaging and capturing software (Applied Imaging, San Jose, CA). Evaluation was independently performed by a minimum of two evaluators (RE, CJL, SP and VS). For each case a minimum of 100 nuclei were assessed.

In cases with co-occurring *ERG* rearrangement and rearrangement of one of the three 5\' partners (i.e., *TMPRSS2, SLC45A3*, or *NDRG1*), we defined these cases harboring a fusion of the rearranged genes.

Statistical analysis {#S6}
--------------------

We investigated for significant association between rearrangement status and clinical parameters including patient age, preoperative PSA serum levels, Gleason score, pathological stage using Pearson Chi-square test. We also investigated for associations between biochemical failure and gene fusion status using Kaplan Meier estimates and log rank test.

RESULTS {#S7}
=======

We were able to assess 540 out of 614 cases for *ERG* rearrangement status. *ERG* rearrangement was identified in 53% (284/540) of the cases ([Figure 1](#F1){ref-type="fig"}). We then characterized *TMPRSS2* and *SLC45A3* rearrangement status in the *ERG* rearrangement positive cases as these are known to be the most common fusion partner for *ERG*. Out of 284, 254 cases were assessable for both *ERG* 5\' partners (i.e., *TMPRSS2* and *SLC45A3*) in addition to the *ERG* rearrangement. *TMPRSS2* rearrangement was observed in 78% (198/254) of the *ERG* rearranged cases. *SLC45A3* was rearranged in 6% (16/254) of these cases. Interestingly, 11% of the *ERG* rearranged cases (27/254) harbored concurrent rearrangements of *SLC45A3* and *TMPRSS2* ([Figure 1](#F1){ref-type="fig"} and [Figure 2](#F2){ref-type="fig"}).

Seven of these 27 cases harbored simultaneous *TMPRSS2* and *SLC45A3* rearrangements within the same tissue microarray core. We evaluated by FISH the original standard tissue block in four of these seven cases. We could confirm that one of them harbored *ERG* rearrangement and coexisting rearrangement of *TMPRSS2* and *SLC45A3* in the same tumor glands ([Figure 3](#F3){ref-type="fig"}). The three remaining cases harbored a mixture of tumor glands with both normal and rearrangement pattern.

*ERG* with rearrangement through deletion mechanism was seen in 62% (158/254) of the *ERG* rearranged cases. *TMPRSS2* was the fusion partner in 82% (130/158) and *SLC45A3* in around 3% (4/158) of these cases, and both 5\' fusion partners were simultaneous rearranged in 10% (16/158) of these *ERG* rearranged cases. *ERG* rearrangement through insertion was detected in 38% (96/254) of cases, with *TMPRSS2* as 5\' fusion partner in 71% (68/96), and *SLC45A3* as 5\' fusion partner in 12% of cases (12/96) ([Figure 4](#F4){ref-type="fig"}). Simultaneous *TMPRSS2* and *SLC45A3* gene rearrangement were identified in 11% of cases (11/96) ([Figure 4](#F4){ref-type="fig"}).

In the 13/254 (5%) *ERG* rearranged cases without a *TMPRSS2* or *SLC45A3* rearrangement, we next sought for *NDRG1* rearrangement. We could assess *NDRG1* in 10 of these 13 cases and one case demonstrated *NDRG1* rearrangement. The 5\' partner of the remaining *ERG* rearranged cases could not accounted for by the three 5\' partners. None of the normal prostatic tissue harbored a rearrangement of *ERG, TMPRSS2, SLC45A3 or NDRG1*.

Statistical analysis revealed no significant association between any of the assessed gene rearrangements and clinical features such as Gleason grade, stage, or PSA recurrence-free survival ([Table 1](#T1){ref-type="table"}).

DISCUSSION {#S8}
==========

Most studies to date are using a FISH break apart assay to determine *TMPRSS2-ERG* fusion status. Therefore, the prevalence of *ERG* rearrangement is well characterized at approximately 40--60% of PSA screened prostate cancer cases. This study confirms that in the vast majority of cases, *ERG* rearrangement is due to *TMPRSS2-ERG* gene fusion either through deletion or insertion. As suggested in a recently published study of 101 prostate cancer cases ([@R20]) and now demonstrated in a significantly larger population of 540 prostate cancer cases, *SLC45A3-ERG* and *NDRG1-ERG* fusion account for around 10% of the *ERG* rearranged tumors. It is yet to be determined if there are any significant implications to these other less common gene fusions. As suggested by Pflueger *et al* ([@R20]), TMPRSS2, *SLC45A3*, and *NDRG1* are all exquisitely driven by both Androgen and Estrogen. A potential difference is that *NDRG1-ERG* fusions do encode for a chimeric protein product ([@R20]), whereas *TMPRSS2-ERG* and *SLC45A3-ERG* fusions encode for a truncated ERG protein. To date no study has addressed the clinical implications of this observation but given that expression profiling of *ERG* and non-*ERG* rearranged prostate cancer samples (n=455) did not reveal any clear subclasses within the *ERG* rearranged category([@R13]), we can speculate that *ERG* over expression is the main alteration associated with the molecular phenotype. From a practical perspective, the current study suggests that performing the *ERG* and *TMPRSS2* rearrangement assays should help classify around 90% of the *ERG* rearranged prostate cancer cases.

The current study focused only on *ERG* rearrangement prostate cancer and did not explore for the frequency of other known ETS rearrangements. Mehra *et al* systematically interrogated all 27 other ETS rearrangements in a cohort of 96 prostate cancer cases and found that after *ERG*, ETV1 was the most commonly rearranged prostate cancer suggesting that *TMPRSS2-ETV1* fusion may in around 2% of prostate cancer cases ([@R23]). Attard et al. examining a cohort of 429 prostate cancer cases found that ETV1 was rearranged in slightly over 5% of the cases ([@R24]). The Attard study also identified other novel 5\' fusion partners besides *TMPRSS2* for *ETV1*. In a recent unpublished study exploring *ETV1, ETV4*, and *ETV5* rearrangements in 88 prostate cancer cases, we identified similar rearrangement frequencies (Svensson *et al*, unpublished data). Therefore, *ERG* and *ETV1* appear to be rearranged in around 40--60% and 2--5% of PSA screened prostate cancer cases, respectively. Other ETS genes such as *ETV4* and *ETV5* may have rearrangement frequencies at or below 1--2%. There appears to be a wider range of recurrent 5\' partners besides the originally described *TMPRSS2* ([@R1]) including *SLC45A3* and *NDRG1*. Only large systematic studies will be able to define any clinical significance to the less common rearrangements.

Consistent with some of the initial descriptions of *ERG* rearranged prostate cancer cases assessed by FISH ([@R1], [@R18], [@R25]), we found approximately 53% of cases harbored an *ERG* rearrangement with 62% of these being rearranged through deletion and 38% being rearranged through insertion. To date there is no known clinical implication associated with these two types of ERG rearrangements. However, we did initially speculate that the region between *TMPRSS2* and *ERG* on chromosome 21 does harbor candidate tumor suppressor genes that might be lost in *ERG* rearrangements through deletion([@R18]).

This is the first study to systematically evaluate for the *SLC45A3-ERG* rearrangement in a large population. Han et al first described this fusion ([@R19]) and the recurrent nature was confirmed more recently by Pflueger et al. ([@R20]). By systematically interrogating 540 prostate cancers, we observe a 6% frequency of *SLC45A3-ERG* fusion prostate cancer. As this study has shown and future studies are sure to observe, that there is more complexity to ETS rearrangements than initially appreciated. Specifically, in our current study around 11% of the individuals harboring *ERG* rearranged, showed coexisting rearrangement of two 5\' fusion partners (i.e., *TMPRSS2* and *SLC45A3*) and seven of them in the same tissue microarray core. This would suggest different possible gene fusion combinations (*TMPRSS2-ERG*, *SLC45A3-ERG* and/or other potentially not yet identified fusions). We were able to evaluate four of these seven specific cases harboring multiple rearrangements on the original tissue block and could confirm that one of them harbored *ERG* rearrangement and both 5\' partners *TMPRSS2* and *SLC45A3* rearrangements in the same tumor glands. One important limitation of our study is that we did not have fresh frozen material from these cases to perform assays that would allow us to characterize the nature of these fusions or explore for novel 5\' fusion partners.

The present study has potential clinical implications for the development of cancer specific diagnostic assays. Pioneering work in prostate cancer biomarker development demonstrated that the PCA3 transcript could be used as a prostate cancer diagnostic test in the urine of men at risk of prostate cancer ([@R26]--[@R30]). This assay is now being offered for clinical use at several national commertial laboratories. Extending this type of assay, several studies have explored using the *TMPRSS2-ERG* fusion transcript as a prostate cancer specific urine biomarker either alone or in combination with other assays ([@R31]--[@R33]). The presence of *TMPRSS2-ERG* fusion transcripts is highly specific for prostate cancer when detected ([@R31], [@R32], [@R34]). However, the sensitivity approaches the theoretical limitations of 40--50% reflecting the prevalence of *TMRPSS2-ERG* fusions in the prostate cancer population. The current study suggests that this sensitivity might be improved by incorporating other common recurrent gene fusions such as *SLC45A3-ERG, TMPRSS2-ETV1, SLC45A3-ETV1*, and *NDRG1-ERG*. As the next generations of these assays are developed, perhaps incorporations of all known gene fusions would be feasable.

Our study of 540 men with clinically localized prostate cancer did not observe any clinical associations between ETS rearrangement status and pathology or clinical parameters. There is considerable controversy and confusion regarding the clinical implications of ETS rearangement prostate cancer (See Tomlins et al. for a review on this subject ([@R4])). Associations with cancer specific death and *ERG* rearrangment prostate cancer were described in two Watchful Waiting cohorts ([@R15], [@R16]). These studies are particular because patients were diagnosed and then followed with prostate cancer without undergoing initial definitive treatment. These studies therefore might represent the natural clinical course of ETS rearrangement prostate cancer. A number of other studies has explored for associations for between PSA biochemical recurrence and ETS rearrangement and have failed to demonstrate any consistent findings (See Tomlins et al. for a review on this subject([@R4]). We posit that these studies can not be used as evidence that ETS rearrangement prostate cancers do not have a more or less aggressive natural history as the course of the tumor progression was interrupted by clinical intervention. In addition, PSA biochemical recurrence has not been demonstrated to be an accurate predictor of cancer cancer specific death ([@R35]). Some have suggested that the frequency of ETS rearrangement prostate cancer cases (40--60%) is too high to represent an aggressive sub-population. This is an imporant observation given the relative low mortality rate of prostate cancer. More recent work by Carver et al. ([@R10]) and King et al. ([@R9]), using animal models suggests that *ERG* over expression alone is insufficient for disease progression and the concurrent *PTEN* loss or alteration of the PI3/AKT/PTEN pathway is required. These studies would suggest that ETS rearragements and other molecular concurrent events may best describe an aggressive clinical cancer. Numerous studies are underway to explore this hypothesis.

In summary, we were able to confirm in a large cohort that around 80% of prostate cancer cases with *ERG* rearrangement have *TMPRSS2-ERG* gene fusions. We also demonstrate the recurrent nature of *SLC45A3-ERG* and *NDRG1-ERG* fusions in approximately 7% of *ERG* rearranged cases. Interestingly in 11% of the cases, we observed prostate cancer cases where individuals harbored more than one type of ERG rearrangement and rarely where two *ERG* fusions appear to occur in the same tumor focus. For the remaining *ERG* rearranged cases we could not confirm the 5\' partner. This study has important clinical implications for the development of diagnostic assays to detect ETS rearrangement prostate cancer. Incorporation of these less common *ERG* rearrangement prostate cancer fusion assays could further increase the sensitivity of these PCR-based approaches.
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![Pie chart summary of study results\
Frequencies of the most common 5\' partners of *ERG* rearranged prostate cancer cases are given in percentages (number of rearranged cases/evaluable cases)](nihms-165730-f0001){#F1}

![Representative example of four similar prostate cancer cases harboring gene rearrangement\
*ERG* rearrangement through deletion (a) *TMPRSS2* rearrangement through deletion (b) SCL45A3 rearrangement (c) and *NDRG1* rearrangement (d) (H&E images are taken at 40x objective magnification and FISH images are taken at 60x objective magnification).](nihms-165730-f0002){#F2}

![Representative example of a case with simultaneous rearrangements of two 5\' fusion partners. Prostatic tissue with prostatic adenocarcinoma (Gleason 3+3=6) and FISH images\
Within the same gland almost all cells harbor *ERG* rearrangement (translocation trough insertion) (a) and both 5\' gene rearrangements, *TMPRSS2* (b) and *SLC45A3* (c). (H&E images are taken at 40x objective magnification and FISH images are taken at 60x objective magnification)](nihms-165730-f0003){#F3}

![Schematic of *ERG* rearrangement](nihms-165730-f0004){#F4}

###### 

Demographic and clinical characteristics of 540 men (all assessable cases) with clinically localized prostate cancer patients by ERG rearrangement status and mechanism.

                                   *ERG* rearranged n= 284   *ERG* not rearranged n= 256   
  -------------------------------- ------------------------- ----------------------------- ---------------
  All assessable cases (**540**)   **178** (63%)             **106** (37%)                 **256** (47%)
  Age                                                                                      
  ≤ 62                             86 (32%)                  63 (23%)                      120 (45%)
  \> 62                            92 (34%)                  43 (16%)                      136 (50%)
  Preoperative PSA (533)                                                                   
  ≤ 10 ng/ml                       130 (24%)                 80 (15%)                      173 (33%)
  \> 10 ng/ml                      47 (9%)                   26 (5%)                       77 (14%)
  pT stage (540)                                                                           
  pT2                              111 (30%)                 72 (20%)                      186 (50%)
  pT3/T4                           67 (39%)                  34 (20%)                      70 (41%)
  Gleason score (540)                                                                      
  3--6                             59 (11%)                  36 (7%)                       89 (16%)
  7                                94 (17%                   51 (9%)                       115 (21%
  8--10                            25 (5%)                   19 (4%)                       52 (10%)
  Biochemical recurrence (515)                                                             
  Yes                              146 (28%)                 86 (17%)                      208 (40%)
  No                               25 (5%)                   16 (3%)                       34 (7%)
  Anti-androgen therapy (538)                                                              
  Yes                              165 (33%)                 102 (20%)                     232 (47%)
  No                               11 (28%)                  4 (10%)                       24 (62%)
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